Gautam Borthakur, MBBS
M.D. Anderson Cancer Center · UT MD Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gautam Borthakur, MBBS as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:30 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07053020 · A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)M.D. Anderson Cancer Center · not yet recruiting · Acute Myeloid Leukemia (AML) · principal investigator
- Ph1/Ph2NCT06548230 · A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)M.D. Anderson Cancer Center · recruiting · Myelodysplastic Syndrome(MDS), Acute Myelogenous Leukemia (AML) · principal investigator
- Ph1/Ph2NCT06113289 · A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid LeukemiaM.D. Anderson Cancer Center · withdrawn · Acute Myeloid Leukemia · principal investigator
- Ph2NCT03207542 · Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)M.D. Anderson Cancer Center · withdrawn · Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic · principal investigator
- Ph2NCT01692197 · E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic SyndromesM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT01222195 · Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph1NCT01029509 · Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic SyndromesM.D. Anderson Cancer Center · terminated · Leukemia · study chair
- Ph2NCT00968071 · Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Acute Myelogenous Leukemia, Myelodysplastic Syndrome · study chair
- Ph2NCT00960726 · NOV-002 in Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · withdrawn · Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph2NCT00520468 · Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDSM.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in acute myeloid leukemia.